0001404644-26-000030
SEC filingNeurogene Inc. expanded its Board to seven directors and appointed President and CFO Christine Mikail as a Class II director, while also naming Christy Shafer as Chief Commercial Officer to lead commercial strategy for NGN-401 gene therapy for Rett syndrome.
The appointments strengthen Neurogene's leadership as the company advances its lead gene therapy program NGN-401 for Rett syndrome. Christine Mikail's elevation to the Board leverages her deep institutional knowledge and strategic expertise gained since joining the company in 2019, providing continuity in governance during a critical phase. Her background includes over two decades in biotech corporate strategy, business development, and finance, with previous roles at Axovant Sciences, NPS Pharmaceuticals, and Eli Lilly. The addition of Christy Shafer as Chief Commercial Officer addresses a key functional gap, bringing specialized experience in rare neurological disease commercialization from Avidity Biosciences and Marinus Pharmaceuticals, where she led successful product launches. These moves signal Neurogene's preparation for potential commercialization of NGN-401 while maintaining financial and operational discipline through Mikail's continued CFO oversight.